In oncology, small molecules, CAR-T therapies, antibody therapies, dominate the current clinical development landscape but innovation continues to push boundaries. When discussing antibody therapeutics, monoclonal and bispecific antibodies often come to the forefront. At ASCO 2025, there will be a spotlight on the next frontier of oncology treatment, i.e., trispecific antibodies. 

At present, several trispecific antibody candidates are in preclinical and clinical development for indications such as cancer, infectious diseases, and ophthalmic conditions. Looking ahead, the clinical pipeline for trispecific therapies is expected to grow and extend into new therapeutic areas, including autoimmune disorders. 

The conference will highlight clinical data of drug candidates designed to target cancers such as Relapsed/Refractory Multiple Myeloma (RRMM), neuroendocrine carcinoma (NEC), and Small Cell Lung Cancer (SCLC), marking a significant step forward in cancer therapeutic innovation. While trispecific antibodies have not yet garnered the same level of attention as bispecifics, companies such as Suzhou Zelgen Biopharmaceuticals (ZG006), Ichnos Sciences (ISB 2001), Janssen Research & Development (JNJ-79635322), and others are actively advancing their development. While early studies of trispecific antibodies [for example; SAR442257 (CD38 x CD28 x CD3 T-Cell engager)] in RRMM have encountered significant challenges, research in myeloma continues to push forward. Despite setbacks, therapies such as ISB 2001 offer renewed optimism for future advancements. 

Key Abstracts of Trispecific Drug Candidates